Agostini F, Masato A, Bubacco L, Bisaglia M (2022) Metformin repurposing for Parkinson disease therapy: opportunities and challenges. Int J Mol Sci 23:398. https://doi.org/10.3390/ijms23010398

Article  CAS  Google Scholar 

Al-kuraishy HM, Al-Gareeb AI, Selim HM et al (2024a) Does vitamin D protect or treat parkinson’s disease? A narrative review. Naunyn Schmiedebergs Arch Pharmacol 397:33–40. https://doi.org/10.1007/s00210-023-02656-6

Article  CAS  PubMed  Google Scholar 

Al-kuraishy HM, Al-Hamash SM, Jabir MS et al (2024b) The classical and non-classical axes of renin-angiotensin system in Parkinson disease: the bright and dark side of the Moon. Ageing Res Rev 94. https://doi.org/10.1016/j.arr.2024.102200

Al-kuraishy HM, Sulaiman GM, Saad HM et al (2025) The effect of Metformin on astrocytes in parkinson’s disease: challenges and opportunities. Mol Neurobiol 1–5. https://doi.org/10.1007/s12035-025-05098-8

Alberini CM (2023) IGF2 in memory, neurodevelopmental disorders, and neurodegenerative diseases. Trends Neurosci 46:488–502. https://doi.org/10.1016/j.tins.2023.03.007

Article  CAS  PubMed  PubMed Central  Google Scholar 

Albert-Gascó H, Ros-Bernal F, Castillo-Gómez E, Olucha-Bordonau FE (2020) Map/erk signaling in developing cognitive and emotional function and its effect on pathological and neurodegenerative processes. Int J Mol Sci 21:1–29. https://doi.org/10.3390/ijms21124471

Article  CAS  Google Scholar 

Alharbi B, Al-kuraishy HM, Al-Gareeb AI et al (2024) Role of GABA pathway in motor and non-motor symptoms in parkinson’s disease: a bidirectional circuit. Eur J Med Res 29:205. https://doi.org/10.1186/s40001-024-01779-7

Article  PubMed  PubMed Central  Google Scholar 

Allard JB, Duan C (2018) IGF-binding proteins: why do they exist and why are there so many? Front Endocrinol (Lausanne) 9:117. https://doi.org/10.3389/fendo.2018.00117

Article  PubMed  PubMed Central  Google Scholar 

Alrouji M, Al-kuraishy HM, Al-Gareeb AI et al (2024) Metformin role in parkinson’s disease: a double-sword effect. Mol Cell Biochem 479:975–991. https://doi.org/10.1007/s11010-023-04771-7

Article  CAS  PubMed  Google Scholar 

Alshahrani SM, Al-kuraishy HM, Al-Gareeb AI et al (2025a) LRP1 at the crossroads of parkinson’s and alzheimer’s: divergent roles in α-synuclein and amyloid pathology. Eur J Pharmacol. https://doi.org/10.1016/j.ejphar.2025.177830. 1002:

Article  PubMed  Google Scholar 

Alshahrani SM, Al-kuraishy HM, Al-Gareeb AI et al (2025b) Dysregulation of the leukotriene pathway in parkinson’s disease: the potential role of Montelukast. Cytokine 194:157010. https://doi.org/10.1016/J.CYTO.2025.157010

Article  CAS  PubMed  Google Scholar 

Alwerdani MM, El-Sayed AS, Hanbal A et al (2022) Serum Insulin-like growth Factor-1 as a biomarker for parkinson’s disease: A systematic review and meta-analysis. (P1-1.Virtual). Neurology 98:2832. https://doi.org/10.1212/WNL.98.18_SUPPLEMENT.2832

Article  Google Scholar 

An J, Wen L, Yu H et al (2024) Insulin-Like growth factor binding protein 2 drives neurodegeneration in parkinson’s disease: insights from in vivo and in vitro studies. CNS Neurosci Ther 30:e70076. https://doi.org/10.1111/cns.70076

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antenyi EF, Momoh OM, Tor NE, POLYMORPHISMS WITHIN THE EXON 3 REGION OF IGF1 GENE OF TWO SAVANNAH MUTURU POPULATIONS IN NIGERIA USING RFLP MARKER (2025) FUDMA J Sci 9:231–236. https://doi.org/10.33003/fjs-2025-0902-3219

Article  Google Scholar 

Arbo BD, Schimith LE, Goulart dos Santos M, Hort MA (2022) Repositioning and development of new treatments for neurodegenerative diseases: focus on neuroinflammation. Eur J Pharmacol 919:174800. https://doi.org/10.1016/j.ejphar.2022.174800

Article  CAS  PubMed  Google Scholar 

Arcos J, Grunenwald F, Sepulveda D et al (2023) IGF2 prevents dopaminergic neuronal loss and decreases intracellular alpha-synuclein accumulation in parkinson’s disease models. Cell Death Discov 9:438. https://doi.org/10.1038/s41420-023-01734-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arjunan A, Sah DK, Woo M, Song J (2023) Identification of the molecular mechanism of insulin-like growth factor-1 (IGF-1): a promising therapeutic target for neurodegenerative diseases associated with metabolic syndrome. Cell Biosci 13:16. https://doi.org/10.1186/s13578-023-00966-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Badawi GA, Shokr MM, Elshazly SM et al (2024) Sigma-1 receptor modulation by clemastine highlights its repurposing as neuroprotective agent against seizures and cognitive deficits in PTZ-kindled rats. Eur J Pharmacol 980:176851. https://doi.org/10.1016/j.ejphar.2024.176851

Article  CAS  PubMed  Google Scholar 

Bathina S, Das UN (2015) Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci 11:1164–1178. https://doi.org/10.5114/aoms.2015.56342

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benarroch EE (2012) Insulin-like growth factors in the brain and their potential clinical implications. Neurology 79:2148–2153. https://doi.org/10.1212/WNL.0b013e3182752eef

Article  PubMed  Google Scholar 

Bernhard FP, Heinzel S, Binder G et al (2016) Insulin-like growth factor 1 (IGF-1) in parkinson’s disease: potential as trait-, progression- and prediction marker and confounding factors. PLoS ONE 11:e0150552. https://doi.org/10.1371/journal.pone.0150552

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bochel AJ, Williams C, McCoy AJ et al (2020) Structure of the human Cation-Independent mannose 6-Phosphate/IGF2 receptor domains 7–11 uncovers the mannose 6-Phosphate binding site of domain 9. Structure 28:1300–1312e5. https://doi.org/10.1016/j.str.2020.08.002

Article  CAS  PubMed  Google Scholar 

Bonham LW, Geier EG, Steele NZR et al (2018) Insulin-like growth factor binding protein 2 is associated with biomarkers of alzheimer’s disease pathology and shows differential expression in Transgenic mice. Front Neurosci 12:476. https://doi.org/10.3389/FNINS.2018.00476/FULL

Article  PubMed  PubMed Central  Google Scholar 

Brismar K, Hilding A, Ansurudeen I et al (2023) Adiponectin, IGFBP-1 and – 2 are independent predictors in forecasting prediabetes and type 2 diabetes

Calabresi P, Mechelli A, Natale G et al (2023) Alpha-synuclein in parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 14:176. https://doi.org/10.1038/s41419-023-05672-9

Article  PubMed  PubMed Central  Google Scholar 

Caprio S, Pilli T, Cantara S et al (2024) Paradoxical effect of dopamine-agonists on IGF-1 in patients with prolactinoma: the role of weight. BMC Endocr Disord 24:94. https://doi.org/10.1186/s12902-024-01622-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Castilla-Cortázar I, Aguirre GA, Femat-Roldán G et al (2020) Is insulin-like growth factor-1 involved in parkinson’s disease development? J Transl Med 2020 181 18:70–. https://doi.org/10.1186/S12967-020-02223-0

Article  Google Scholar 

Chen W, He B, Tong W et al (2019) Astrocytic insulin-like growth factor-1 protects neurons against excitotoxicity. Front Cell Neurosci 13:298. https://doi.org/10.3389/fncel.2019.00298

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chesik D, De Keyser J, Wilczak N (2008) Insulin-like growth factor system regulates oligodendroglial cell behavior: therapeutic potential in CNS. J Mol Neurosci 2008 351 35:81–90. https://doi.org/10.1007/S12031-008-9041-2

Article  Google Scholar 

Chung JY, Lee SJ, Lee SH et al (2011) Direct interaction of α-synuclein and AKT regulates IGF-1 signaling: implication of Parkinson disease. Neurosignals 19:86–96. https://doi.org/10.1159/000325028

Article  CAS  PubMed  Google Scholar 

Colonna M, Butovsky O (2017) Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol 35:441–468. https://doi.org/10.1146/annurev-immunol-051116-052358

Article  CAS  PubMed